Oral Treatment Strategies in CLL

Agenda

First-Line Treatment of CLL

Phase 3 iLLUMINATE Study Ibrutinib + Obinutuzumab vs Chlorambucil + Obinutuzumab

Ibrutinib Alone or in Combination With Rituximab vs Bendamustine + Rituximab

Ibrutinib + Rituxumab vs FCR

iFCG for First-Line Treatment of CLL Study Design

iFCG for First-Line Treatment of CLL Study Results

Phase 2 Study of Ibrutinib + Venetoclax in High-Risk Patients

PCYC-1102 Phase 1b/2 Study 7 Years of Follow-Up of Single-Agent Ibrutinib

ACE-CL-001: Phase 1/2 Study of Acalabrutinib

Relapsed/Refractory CLL

Durability of Responses After Drug Cessation of Venetoclax and Rituximab

Phase 3 MURANO Study of VenR vs BR Long-Term Follow-Up

Phase 3 MURANO Study Analysis of PB MRD

Genetic Mutations Associated With Resistance to Venetoclax and Ibrutinib

CLARITY Study of Ibrutinib + Venetoclax PB and BM MRD

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in CLL

Durable Remissions after Treatment Discontinuation in CLL With del(17p)/TP53 Mutations

JCAR017

Anti-CD19 CAR T Cells in Combination With Ibrutinib for the Treatment of CLL

Phase 2 Study of Nivolumab + Ibrutinib in RT

CLL14 Study Design

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)